



27 November 2024

The Manager
ASX Market Announcements
ASX Limited
Exchange Centre
Level 4, 20 Bridge Street
Sydney NSW 2000

In accordance with ASX Listing Rule 3.13.3, Hearts and Minds Investments Limited (ASX:HM1) attaches a copy of the address and presentation to be given at today's Annual General Meeting by HM1 Chair, Mr Chris Cuffe.

For and on behalf of the board,

A handwritten signature in black ink that reads "Eryl Baron". The signature is written in a cursive, flowing style.

Eryl Baron
Company Secretary

Hearts and Minds Investments Limited

Chairman's Address at 2024 Annual General Meeting

Good afternoon and welcome to the sixth Annual General Meeting of Hearts and Minds Investments Limited (which I will refer to as HM1 or the Company). My name is Chris Cuffe, and I am Chair of the Company.

It is good to be holding our AGM in person. It is also great to see that many of our shareholders have joined us online via the Lumi platform. The hybrid meeting allows as many shareholders as possible to participate in the meeting. Shareholders who are online can listen to the live webcast of the meeting, ask questions and submit votes. It is now past 3.00 pm, and I have been informed that there is a quorum present, and I declare the meeting open.

I am joined today by my fellow Directors and company officers: Lorraine Berends (also Chair of the Investment Committee), Matthew Grounds, Michael Traill, Guy Fowler, Gary Weiss, Geoff Wilson, David Wright (also Chair of the Conference Fund Manager Selection Committee), Paul Rayson (Chief Executive Officer), Maggie O'Neill (Head of Marketing and Operations), Charlie Lanchester (Chief Investment Officer) and our Company Secretary, Eryl Baron.

On behalf of the Board and management I would like to thank you for your support of HM1. I will address the Company's financial results and charitable donations for the year ended 30 June 2024 and touch on our recent investment performance.

Richard King from our auditors, Pitcher Partners, is also present, and will be available to address any questions relating to the audit of the Company's financial statements.

FY24 in Review

As you know, HM1 is a listed investment company that was established in 2018 with the combined objective of providing a concentrated global equities portfolio of the highest conviction ideas from respected fund managers, whilst also supporting Australian medical research organisations. It was born out of the investment and philanthropic vision of the Sohn Hearts & Minds Investment Leaders Conference.

Investment Performance

I am pleased to report that, following the changes we made to the management of our investment portfolio 18 months ago, HM1's investment performance has improved. The HM1 investment portfolio increased by 11.7% for the year ended 30 June 2024, building on gains made in the prior year. The current year's investment performance was primarily driven by the technology holdings in our Core Portfolio and a solid return from the 2023 Conference Portfolio.

Over the last four months since the end of the financial year, HM1's investment performance has continued to improve. The one year investment performance to 31 October 2024 was up 32% bringing the annualised investment performance since inception to 10.7%.

Share Price

HM1's share price increased from \$2.26 on 30 June 2023 to \$2.58 on 30 June 2024. The share price discount to NTA per share narrowed to a 17% discount to HM1's pre-tax NTA of \$3.09 on 30 June 2024. The improvement in the share price and the payment of 14 cents in fully franked dividends resulted in a total shareholder return for FY24 of 20%.

Since 30 June 2024, the NTA and the share price has continued to improve with the pre-tax NTA increasing to \$3.47 and the share price increasing to \$3.07 as of last Friday. The share price has increased 38% in the year to 31 October 2024 and the share price discount has further narrowed to 12%. The Board remains confident that sustained improvement in investment performance, our fully franked dividend yield and deepening shareholder engagement will continue to narrow the share price discount to HM1's NTA per share.

Dividends

During the financial year ended 30 June 2024, HM1 paid fully franked dividends amounting to 14 cents per share. You may recall from last year we modified the dividend policy to increase the frequency of dividend payments to twice yearly. We are pleased to report that we also declared an increased half-yearly fully franked dividend of 7.5 cents per share which was paid in October 2024. Based on the current share price the increased annualised dividend represents a fully franked dividend yield of 5.1%.

The Board aims to maintain a policy of paying fully franked dividends to shareholders subject to sufficient cash reserves, available franking credits and prudent business practice. As of 30 June 2024, HM1 had a Realised Profits Reserve equating to 58 cents per share and a Franking Account balance equating to 42 cents per share. Subject to the usual caveats, the Board is confident it can maintain its dividend policy for the foreseeable future.

Investment in Medical Research

In line with its philanthropic objective, HM1 provides financial contributions equivalent to 1.5% of NTA per annum to leading Australian medical research organisations, to fund the development of new medicines and treatments and to drive a new generation of medical research in Australia. This is effectively funded by HM1's participating fund managers, its Board of Directors and Committees and many of our service providers all working on a pro bono basis. We sincerely thank everyone for their ongoing involvement and generosity.

During the year ended 30 June 2024, HM1 paid \$9.4 million to its designated medical research organisations and made provision for a further \$6.4 million. These donated monies will be used by the medical research organisations to fund important research into the prevention and treatment of chronic diseases and mental health disorders.

Including donations made by the HM1 owned and run, Sohn Hearts & Minds Investment Leaders Conference, Hearts and Minds has now donated over \$70m to medical research in Australia. This is a significant contribution to the advancement of medical research in Australia. Your shareholding in HM1 not only delivers investment returns and dividends: Your shareholding is also making a meaningful difference to the prevention, diagnosis and treatment of chronic diseases for your fellow Australians. Further details on the impact of your contribution to medical research can be found on our Impact Website: heartsandmindsgroup.com.au

Conclusion

In conclusion, we believe that HM1 offers a compelling investment in a concentrated portfolio of global equities recommended by a select panel of successful fund managers. The investment returns of the portfolio are underpinned by a fully franked dividend that is paid twice yearly to shareholders. All investment fees are waived and instead, an equivalent amount is contributed to fund medical research in Australia. This represents a professionally curated and managed investment in global equities that also delivers meaningful social returns.



Hearts and Minds Investments

(ASX: HM1)

AGM | November 2024



Welcome

Board of Directors



Chris Cuffe AO
Chair



Lorraine Berends
Director



Guy Fowler
Director



Matthew Grounds AM
Director



Michael Traill AM
Director



Gary Weiss AM
Director



Geoff Wilson AO
Director



David Wright
Director

HM1 Team



Paul Rayson
Chief Executive Officer



Charlie Lanchester
Chief Investment Officer



Maggie O'Neill
Head of Marketing &
Operations



Jessica Safour
Marketing & Office
Manager

Disclaimer



The information to be presented today is general information only and is not a securities recommendation or statement of opinion intended to influence any person in making an investment decision. You should consider seeking independent professional advice before making any investment decision.

27 November 2024

HM1 Overview



1

CONCENTRATED GLOBAL PORTFOLIO

Concentrated global portfolio of long equity positions in 25-35 securities.

2


DIVERSE PORTFOLIO

15+ different fund manager’s investment approaches, expertise and styles.

3

ACCESS TO HIGH CONVICTION IDEAS – NO FEES

Highest conviction ideas from selected fund managers; no fees, no minimum investment.



4

ATTRACTIVE DIVIDEND YIELD

Currently 5.1% fully franked.

5

IMPACT

1.5% of NTA donated to medical research.
Currently \$10m per annum.

6


CURRENTLY TRADING AT DISCOUNT TO NTA

Gain access to HM1 portfolio at 12% discount to NTA.

HM1 Dividend Policy



The Board is targeting the payment of a consistent fully franked twice yearly dividends, subject to sufficient cash reserves, available franking credits and prudent business practice.



Profit Reserve¹

58cps

Franking Account¹

42cps

¹ at 30 June 2024. Franking account represents the level of future dividends (expressed as cents per share) able to be fully franked.

Investing in Australian Medical Research



Proudly one of Australia’s top 30 corporate philanthropists

Medical research funding - FY24

Cumulative medical research funding by HM1 and Sohn Hearts & Minds Conference

\$9.4m

\$70.1m



HM1 Overview



1

CONCENTRATED GLOBAL PORTFOLIO

Concentrated global portfolio of long equity positions in 25-35 securities.

2


DIVERSE PORTFOLIO

15+ different fund manager’s investment approaches, expertise and styles.

3

ACCESS TO HIGH CONVICTION IDEAS – NO FEES

Highest conviction ideas from selected fund managers; no fees, no minimum investment.



4

ATTRACTIVE DIVIDEND YIELD

Currently 5.1% fully franked.

5

IMPACT

1.5% of NTA donated to medical research.
Currently \$10m per annum.

6

CURRENTLY TRADING AT DISCOUNT TO NTA

Gain access to HM1 portfolio at 12% discount to NTA.

HM1 Investment Performance

to 31 October 2024



HM1 Investment Performance	1 month	6 months	1 year	3 years p.a.	Since Inception p.a.
HM1 Investment Performance	2.1%	12.0%	32.2%	-1.6%	10.7%
MSCI World Index (AUD)	3.5%	9.0%	27.2%	9.5%	12.1%

HM1 Investment Performance is calculated after expenses and before taxes. The comparator is the MSCI World price index in AUDSource: Citco Fund Services and www.msci.com. Inception 14 Nov 2018.

HM1 Dividend History	FY21	FY22	FY23	FY24	FY25 (interim)
Dividends Paid – fully franked	12cps	13.5cps	13.5cps	14.0cps	7.5cps

Core Fund Managers

Represents 65% of the portfolio



HM1 Investment Committee
Lorraine Berends (Chair); Chris Cuffe AO; Brett Paton; David Wright; Matthew Grounds AM; Paul Rayson (CEO)

CIO, Charlie Lanchester



CALEDONIA

COOPER
INVESTORS

MAGELLAN
EXPERTS IN GLOBAL INVESTING

MUNIRO

REGAL
FUNDS

tdm.
GROWTH PARTNERS


Tribeca
Investment Partners

Top 10 Holdings - Core Managers

At 22 November 2024



Amazon
AMZN.NAS



Block Inc
SQ.NYSE



Formula One Group
FWONK.NAS



Guzman Y Gomez



Intercontinental Exchange Ltd
ICE.NYSE



Mastercard In
MA.NYSE



Microsoft Corporation
MSFT.NAS



Nvidia
NVDA.NAS



TSMC
TSM.NYSE



Zillow Group Inc
Z.NAS

2024 Conference Fund Managers























Represents 35% of the portfolio



Conference Fund Manager Selection Committee

David Wright (Chair); Dr Gary Weiss AM; Michael Walsh; Charlie Lanchester (CIO)

Fund managers & stock picks

 <div>Rikki Bannan IFM Investors (AUS)</div>	 <div>Jeremy Bond Terra Capital (AUS)</div>	 <div>Sumit Gautam Scalar Gauge Fund (USA)</div>	 <div>Jordan Katz Advent International (USA)</div>	 <div>Beeneet Kothari Tekne Capital Management (USA)</div>	 <div>Chris Kourtis Ellerston Capital (AUS)</div>
 <div>Corporate Travel Management ASX: CTD</div>	 <div>Coeur Mining, Inc. NYSE: CDE</div>	 <div>BlackLine, Inc. NASDAQ: BL</div>	 <div>TransDigm Group Incorporated NYSE: TDG</div>	 <div>DiDi Global Inc. DIDIY: OTC</div>	 <div>Perpetual Limited PPT: ASX</div>
 <div>Samir Mehta J O Hambro Capital Mgmt (SG)</div>	 <div>Alex Pollak Loftus Peak (AUS)</div>	 <div>Vihari Ross Antipodes Partners (AUS)</div>	 <div>Ricky Sandler Eminence Capital (USA)</div>	 <div>Fleur Wright Northcape Capital (AUS)</div>	
 <div>Tencent Music Entertainment Group NYSE: TME</div>	 <div>Eli Lilly and Company NYSE: LLY</div>	 <div>Airbus SE EPA: AIR</div>	 <div>Cellnex Telecom S.A. BME: CLNX</div>	 <div>The Estée Lauder Companies Inc. NYSE: EL</div>	



Hearts and Minds Investments

(ASX: HM1)

Questions

AGM | November 2024

